Journal of Clinical Endocrinology & Metabolism, Vol 74, 177-183, Copyright © 1992 by Endocrine Society

ARTICLES

Insulin-like growth factor-binding protein-3 is functionally normal in pregnancy serum

AM Suikkari and RC Baxter
Department of Endocrinology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Insulin-like growth factor-binding protein-3 (IGFBP-3) carries most of the serum IGFs as a 150K ternary complex which increases during pregnancy. However, recent studies have demonstrated that IGFBP-3 is absent in pregnancy serum when measured by ligand blotting after electrophoresis. In the present study we demonstrate that, by several criteria, IGFBP-3 appears functionally intact in pregnancy serum. Serum samples were collected from pregnant women between 2-40 weeks gestation. Serum immunoreactive IGFBP-3 and acid-labile (alpha) subunit increased linearly throughout pregnancy. Ligand blotting confirmed diminution of IGFBP-3 at 2 weeks gestation and complete absence after 4 weeks gestation or when nonpregnancy serum was preincubated with amniotic fluid. When less harsh methods (neutral chromatography or transient acidification) were used, IGFBP-3 appeared functionally normal in pregnancy serum. Fractionation of pregnancy serum by Superose- 12 gel permeation chromatography showed similar elution profiles for both IGFBP-3 and alpha-subunit compared to those for nonpregnancy serum. Preincubation of nonpregnancy serum with pregnancy serum or amniotic fluid had no effect on IGFBP-3 recovery. After acidification and neutralization of serum to destroy endogenous alpha-subunit, ternary complex formation, measured by radiolabeled alpha-subunit binding, was essentially identical in all nonpregnancy and pregnancy serum, except for a slight loss of activity in first trimester serum. Since the 150K complex cannot form unless IGFBP-3 binds IGFs and alpha- subunit normally, these results suggest that IGFBP-3 in native pregnancy serum is functionally normal.

This article has been cited by other articles:

				L. D. Payet, S. M. Firth, and R. C. Baxter The Role of the Acid-Labile Subunit in Regulating Insulin-Like Growth Factor Transport across Human Umbilical Vein Endothelial Cell Monolayers J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2382 - 2389. [Abstract] [Full Text] [PDF]

				S. M. Firth and R. C. Baxter Cellular Actions of the Insulin-Like Growth Factor Binding Proteins Endocr. Rev., December 1, 2002; 23(6): 824 - 854. [Abstract] [Full Text] [PDF]

				R. C. Baxter, S. Meka, and S. M. Firth Molecular Distribution of IGF Binding Protein-5 in Human Serum J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 271 - 276. [Abstract] [Full Text] [PDF]

				R. C. Baxter What Is the Significance of IGF-Binding Protein-3 Proteolysis in the Circulation? J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 5087 - 5088. [Full Text] [PDF]

				J. Nygren, C. Carlsson-Skwirut, K. Brismar, A. Thorell, O. Ljungqvist, and P. Bang Insulin infusion increases levels of free IGF-I and IGFBP-3 proteolytic activity in patients after surgery Am J Physiol Endocrinol Metab, October 1, 2001; 281(4): E736 - E741. [Abstract] [Full Text] [PDF]

				F. F. LAUSZUS, J. G. KLEBE, and A. FLYVBJERG Macrosomia Associated With Maternal Serum Insulin-Like Growth Factor-I and -II in Diabetic Pregnancy Obstet. Gynecol., May 1, 2001; 97(5): 734 - 741. [Abstract] [Full Text] [PDF]

				R. C. Baxter Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities Am J Physiol Endocrinol Metab, June 1, 2000; 278(6): E967 - E976. [Abstract] [Full Text] [PDF]

				J. A. Coverley, J. L. Martin, and R. C. Baxter The Effect of Phosphorylation by Casein Kinase 2 on the Activity of Insulin-Like Growth Factor-Binding Protein-3 Endocrinology, February 1, 2000; 141(2): 564 - 570. [Abstract] [Full Text] [PDF]

				C. Skjærbæk, J. Frystyk, H. Ørskov, P. Kissmeyer-Nielsen, M. B. Jensen, S. Laurberg, N. Møller, and A. Flyvbjerg Differential Changes in Free and Total Insulin-Like Growth Factor I after Major, Elective Abdominal Surgery: The Possible Role of Insulin-Like Growth Factor-Binding Protein-3 Proteolysis J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2445 - 2449. [Abstract] [Full Text]

				B. Kubler, S. Cowell, J. Zapf, and T. Braulke Proteolysis of Insulin-Like Growth Factor Binding Proteins by a Novel 50-Kilodalton Metalloproteinase in Human Pregnancy Serum Endocrinology, April 1, 1998; 139(4): 1556 - 1563. [Abstract] [Full Text] [PDF]

				S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text]

				R. C. Baxter The Binding Protein's Binding Protein-- Clinical Applications of Acid-Labile Subunit (ALS) Measurement J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 3941 - 3943. [Full Text] [PDF]

				P. Bang and P. J. Fielder Human Pregnancy Serum Contains at Least Two Distinct Proteolytic Activities with the Ability To Degrade Insulin-Like Growth Factor Binding Protein-3 Endocrinology, September 1, 1997; 138(9): 3912 - 3917. [Abstract] [Full Text] [PDF]

				H. Salahifar, R. C. Baxter, and J. L. Martin Insulin-like Growth Factor Binding Protein (IGFBP)-3 Protease Activity Secreted by MCF-7 Breast Cancer Cells: Inhibition by IGFs Does Not Require IGF-IGFBP Interaction Endocrinology, April 1, 1997; 138(4): 1683 - 1690. [Abstract] [Full Text] [PDF]